Eyebright Premium Blend 694 mg
On sale on the US market (according to the DSLD)
Nature's Way, food supplement from the US market
Eyebright Premium Blend 694 mg (Nature's Way), a food supplement au code-barres 033674003800, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Nature's Way
- Barcode
- 033674003800
- Form
- Capsule
- One serving
- 2 capsules
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Hypromellose
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Eyebright Blend | Blend | 694 mg |
| Eyebright | Plant | not stated |
| Raspberry | Plant | not stated |
| Cayenne (Capsicum annuum) | Plant | not stated |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Eyebright Herbal Blend
Entered into DSLD on 23 April 2024. On sale on the US market (according to the DSLD).- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
Official label: Eyebright Herbal Blend
Entered into DSLD on 24 October 2023. Withdrawn from the US market on 11 August 2023 (according to the DSLD).- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
Official label: Eyebright Herbal Blend 916 mg
Entered into DSLD on 27 July 2021. Withdrawn from the US market on 27 June 2022 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient added : Total Carbohydrates (< 1 Gram(s))
- Active ingredient removed : Cayenne (quantity not stated)
- Different quantity per serving : Eyebright Blend: 916 mg in this version; 694 mg on the displayed label
Official label: Eyebright Blend 458 mg
Entered into DSLD on 7 January 2019. Withdrawn from the US market on 28 May 2021 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
- Different quantity per serving : Eyebright Blend: 916 mg in this version; 694 mg on the displayed label
Official label: Eyebright Blend 458 mg
Entered into DSLD on 20 November 2017. Withdrawn from the US market on 21 June 2018 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
- Different quantity per serving : Eyebright Blend: 916 mg in this version; 694 mg on the displayed label
Official label: Eyebright Blend
Entered into DSLD on 24 March 2016. Withdrawn from the US market on 16 June 2016 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
- Different quantity per serving : Eyebright Blend: 916 mg in this version; 694 mg on the displayed label
Official label: Eyebright
Entered into DSLD on 24 November 2015. Withdrawn from the US market on 25 February 2016 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient added : Proprietary Blend (916 mg)
- Active ingredient added : Red Raspberry (quantity not stated)
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Eyebright Blend (694 mg)
- Active ingredient removed : Raspberry (quantity not stated)
Official label: Eyebright
Entered into DSLD on 25 November 2014. Withdrawn from the US market on 9 November 2015 (according to the DSLD).- Active ingredient added : Bayberry (quantity not stated)
- Active ingredient added : Cayenne Pepper (quantity not stated)
- Active ingredient added : Goldenseal (quantity not stated)
- Active ingredient added : Proprietary Blend (915 mg)
- Active ingredient added : Red Raspberry (quantity not stated)
- Active ingredient added : Total Carbohydrates (< 1 Gram(s))
- Active ingredient removed : Cayenne (quantity not stated)
- Active ingredient removed : Eyebright Blend (694 mg)
- Active ingredient removed : Raspberry (quantity not stated)
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Cayenne
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Has the product changed? Photograph the packaging.
Brand : Nature's Way
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Eyebright Premium Blend 694 mg (Nature's Way): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/33674003800-eyebright-premium-blend-694-mg-nature-s-way, updated 25 June 2025.